Hematology

Acute Lymphoblastic Leukemia

Previously Untreated
- Age 18-39
  - SWOG041501
    - Phase III
    - Inotuzumab and Ozogamicin
    - (Anti-CD22 Mab) vs Frontline Tx in Newly Diagnosed Precursor B-Cell ALL
    - PI: Liedtke
    - SWOG

- Age 50+
  - SWOG042001
    - Randomized Phase II Study
    - Comparing Inotuzumab Plus Chemotherapy vs Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
    - PI: Liedtke
    - Sponsor: SWOG

Relapsed/Refractory
- HEM0060
  - COVALENT-101: First-In-Human Dose-Escalation & Dose-Expansion Study of BMF-219 (Oral, Covalent, Menin Inhibitor) in Acute Leukemia (AL) Diffuse Large B-cell Lymphoma (DLBCL) Multiple Myeloma (MM) & Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
  - PI: Liedtke
  - Sponsor: Biomea Fusion, Inc.

CD19-Positive
- CCT5052
  - Phase I Open Label Dose Escalation Study of YT0323 in CLL/SLL and DLBCL
  - PI: Coutre
  - Novartis

KEY
- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Optional Path
- Enrollment on Hold